Coherus Oncology

CHRSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$200.851 M

$1.30 -5.11%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

$168.0M

#1075 by earnings

Shares outstanding

154,500,966

Latest filing cover page

P/E ratio

1.2

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#97SurrozenSRZN$206.9M
#98Innate PharmaIPHA$201.1M
#99Coherus OncologyCHRS$200.9M
#100Precision BiosciencesDTIL$198.5M
#101Voyager TherapeuticsVYGR$193.5M

What if Coherus Oncology were worth as much as…

Open the what-if tool →

Gold $30.2T

$195,687.90

Per share 150,529× higher

Bitcoin $1.74T

$11,272.78

Per share 8,671× higher

Nvidia $5.52T

$35,700.53

Per share 27,462× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Coherus Oncology are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.